File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/978-3-319-24932-2_10
- Scopus: eid_2-s2.0-84951875229
- PMID: 26703805
- WOS: WOS:000369068700011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Book Chapter: Personalized radiation therapy (PRT) for lung cancer
Title | Personalized radiation therapy (PRT) for lung cancer |
---|---|
Authors | |
Keywords | Personalized radiation therapy Radiomics Lung cancer Biomarkers Adaptive radiation therapy |
Issue Date | 2016 |
Citation | Personalized Radiation Therapy (PRT) for Lung Cancer. In Ahmad, A and Gadgeel, S (Eds), Advances in Experimental Medicine and Biology, v. 890, p. 175-202. Cham : Springer, 2016 How to Cite? |
Abstract | © Springer International Publishing Switzerland 2016. This chapter reviews and discusses approaches and strategies of personalized radiation therapy (PRT) for lung cancers at four different levels: (1) clinically established PRT based on a patient’s histology, stage, tumor volume and tumor locations; (2) personalized adaptive radiation therapy (RT) based on image response during treatment; (3) PRT based on biomarkers; (4) personalized fractionation schedule. The current RT practice for lung cancer is partially individualized according to tumor histology, stage, size/location, and combination with use of systemic therapy. During-RT PET-CT image guided adaptive treatment is being tested in a multicenter trial. Treatment response detected by the during-RT images may also provide a strategy to further personalize the remaining treatment. Research on biomarker-guided PRT is ongoing. The biomarkers include genomics, proteomics, microRNA, cytokines, metabolomics from tumor and blood samples, and radiomics from PET, CT, SPECT images. Finally, RT fractionation schedule may also be personalized to each individual patient to maximize therapeutic gain. Future PRT should be based on comprehensive considerations of knowledge acquired from all these levels, as well as consideration of the societal value such as cost and effectiveness. |
Persistent Identifier | http://hdl.handle.net/10722/267019 |
ISBN | |
ISSN | 2021 Impact Factor: 3.650 2023 SCImago Journal Rankings: 0.244 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jin, Jian Yue | - |
dc.contributor.author | Kong, Feng Ming (Spring) | - |
dc.date.accessioned | 2019-01-31T07:20:16Z | - |
dc.date.available | 2019-01-31T07:20:16Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Personalized Radiation Therapy (PRT) for Lung Cancer. In Ahmad, A and Gadgeel, S (Eds), Advances in Experimental Medicine and Biology, v. 890, p. 175-202. Cham : Springer, 2016 | - |
dc.identifier.isbn | 9783319249315 | - |
dc.identifier.issn | 0065-2598 | - |
dc.identifier.uri | http://hdl.handle.net/10722/267019 | - |
dc.description.abstract | © Springer International Publishing Switzerland 2016. This chapter reviews and discusses approaches and strategies of personalized radiation therapy (PRT) for lung cancers at four different levels: (1) clinically established PRT based on a patient’s histology, stage, tumor volume and tumor locations; (2) personalized adaptive radiation therapy (RT) based on image response during treatment; (3) PRT based on biomarkers; (4) personalized fractionation schedule. The current RT practice for lung cancer is partially individualized according to tumor histology, stage, size/location, and combination with use of systemic therapy. During-RT PET-CT image guided adaptive treatment is being tested in a multicenter trial. Treatment response detected by the during-RT images may also provide a strategy to further personalize the remaining treatment. Research on biomarker-guided PRT is ongoing. The biomarkers include genomics, proteomics, microRNA, cytokines, metabolomics from tumor and blood samples, and radiomics from PET, CT, SPECT images. Finally, RT fractionation schedule may also be personalized to each individual patient to maximize therapeutic gain. Future PRT should be based on comprehensive considerations of knowledge acquired from all these levels, as well as consideration of the societal value such as cost and effectiveness. | - |
dc.language | eng | - |
dc.relation.ispartof | Advances in Experimental Medicine and Biology | - |
dc.subject | Personalized radiation therapy | - |
dc.subject | Radiomics | - |
dc.subject | Lung cancer | - |
dc.subject | Biomarkers | - |
dc.subject | Adaptive radiation therapy | - |
dc.title | Personalized radiation therapy (PRT) for lung cancer | - |
dc.type | Book_Chapter | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1007/978-3-319-24932-2_10 | - |
dc.identifier.pmid | 26703805 | - |
dc.identifier.scopus | eid_2-s2.0-84951875229 | - |
dc.identifier.volume | 890 | - |
dc.identifier.spage | 175 | - |
dc.identifier.epage | 202 | - |
dc.identifier.eissn | 2214-8019 | - |
dc.identifier.isi | WOS:000369068700011 | - |
dc.identifier.issnl | 0065-2598 | - |